{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:27:37Z","timestamp":1758400057270,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K08632","18K07885","21K07804"],"award-info":[{"award-number":["17K08632","18K07885","21K07804"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanofi AS","award":["Investigator-Research Support grant"],"award-info":[{"award-number":["Investigator-Research Support grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s12185-022-03468-9","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T03:20:16Z","timestamp":1665717616000},"page":"56-67","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Modified expi293 cell culture system using piggyBac transposon enables efficient production of human FVIII"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7856-0679","authenticated-orcid":false,"given":"Takuji","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruto","family":"Shimonishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoji","family":"Horie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"issue":"6","key":"3468_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","volume":"357","author":"MJ Manco-Johnson","year":"2007","unstructured":"Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535\u201344.","journal-title":"N Engl J Med"},{"issue":"2","key":"3468_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1042\/BA20010082","volume":"35","author":"HS Kingdon","year":"2002","unstructured":"Kingdon HS, Lundblad RL. An adventure in biotechnology: the development of haemophilia A therapeutics\u2014from whole-blood transfusion to recombinant DNA to gene therapy. Biotechnol Appl Biochem. 2002;35(2):141\u20138.","journal-title":"Biotechnol Appl Biochem"},{"key":"3468_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.omtm.2020.10.013","volume":"19","author":"W Cao","year":"2020","unstructured":"Cao W, Dong B, Horling F, Firrman JA, Lengler J, Klugmann M, et al. Minimal essential human factor VIII alterations enhance secretion and gene therapy efficiency. Mol Ther Methods Clin Dev. 2020;19:486\u201395.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"3468_CR4","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/biot.201400666","volume":"10","author":"SR Kumar","year":"2015","unstructured":"Kumar SR. Industrial production of clotting factors: challenges of expression, and choice of host cells. Biotechnol J. 2015;10(7):995\u20131004.","journal-title":"Biotechnol J"},{"issue":"2","key":"3468_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1006\/bcmd.2002.0508","volume":"28","author":"S Soukharev","year":"2002","unstructured":"Soukharev S, Hammond D, Ananyeva NM, Anderson JA, Hauser CA, Pipe S, et al. Expression of factor VIII in recombinant and transgenic systems. Blood Cells Mol Dis. 2002;28(2):234\u201348.","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"3468_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/21655979.2017.1279767","volume":"8","author":"K Swiech","year":"2017","unstructured":"Swiech K, Picanco-Castro V, Covas DT. Production of recombinant coagulation factors: are humans the best host cells? Bioengineered. 2017;8(5):462\u201370.","journal-title":"Bioengineered"},{"issue":"5","key":"3468_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.thromres.2012.08.311","volume":"130","author":"H Sandberg","year":"2012","unstructured":"Sandberg H, Kannicht C, Stenlund P, Dadaian M, Oswaldsson U, Cordula C, et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res. 2012;130(5):808\u201317.","journal-title":"Thromb Res"},{"key":"3468_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.copbio.2014.06.010","volume":"30","author":"M Butler","year":"2014","unstructured":"Butler M, Spearman M. The choice of mammalian cell host and possibilities for glycosylation engineering. Curr Opin Biotechnol. 2014;30:107\u201312.","journal-title":"Curr Opin Biotechnol"},{"issue":"8","key":"3468_CR9","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nbt.1651","volume":"28","author":"D Ghaderi","year":"2010","unstructured":"Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol. 2010;28(8):863\u20137.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"3468_CR10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.copbio.2009.10.008","volume":"20","author":"Y Durocher","year":"2009","unstructured":"Durocher Y, Butler M. Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol. 2009;20(6):700\u20137.","journal-title":"Curr Opin Biotechnol"},{"key":"3468_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5661\/bger-28-147","volume":"28","author":"D Ghaderi","year":"2012","unstructured":"Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev. 2012;28:147\u201375.","journal-title":"Biotechnol Genet Eng Rev"},{"issue":"1","key":"3468_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1055\/s-0037-1612910","volume":"85","author":"H Sandberg","year":"2001","unstructured":"Sandberg H, Almstedt A, Brandt J, Gray E, Holmquist L, Oswaldsson U, et al. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost. 2001;85(1):93\u2013100.","journal-title":"Thromb Haemost"},{"issue":"3","key":"3468_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cell.2005.07.013","volume":"122","author":"S Ding","year":"2005","unstructured":"Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell. 2005;122(3):473\u201383.","journal-title":"Cell"},{"issue":"4","key":"3468_CR14","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1073\/pnas.1008322108","volume":"108","author":"K Yusa","year":"2011","unstructured":"Yusa K, Zhou L, Li MA, Bradley A, Craig NL. A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci U S A. 2011;108(4):1531\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3468_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pep.2017.03.018","volume":"134","author":"NK Jain","year":"2017","unstructured":"Jain NK, Barkowski-Clark S, Altman R, Johnson K, Sun F, Zmuda J, et al. A high density CHO-S transient transfection system: comparison of ExpiCHO and Expi293. Protein Expr Purif. 2017;134:38\u201346.","journal-title":"Protein Expr Purif"},{"issue":"5","key":"3468_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nmeth.1323","volume":"6","author":"K Yusa","year":"2009","unstructured":"Yusa K, Rad R, Takeda J, Bradley A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods. 2009;6(5):363\u20139.","journal-title":"Nat Methods"},{"issue":"2","key":"3468_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","volume":"108","author":"H Niwa","year":"1991","unstructured":"Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991;108(2):193\u20139.","journal-title":"Gene"},{"issue":"3","key":"3468_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0014-5793(97)00313-X","volume":"407","author":"M Okabe","year":"1997","unstructured":"Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. \u201cGreen mice\u201d as a source of ubiquitous green cells. FEBS Lett. 1997;407(3):313\u20139.","journal-title":"FEBS Lett"},{"issue":"2","key":"3468_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood-2001-12-0361","volume":"100","author":"PV Jenkins","year":"2002","unstructured":"Jenkins PV, Freas J, Schmidt KM, Zhou Q, Fay PJ. Mutations associated with hemophilia A in the 558\u2013565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex. Blood. 2002;100(2):501\u20138.","journal-title":"Blood"},{"issue":"2","key":"3468_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/jth.12474","volume":"12","author":"A Muto","year":"2014","unstructured":"Muto A, Yoshihashi K, Takeda M, Kitazawa T, Soeda T, Igawa T, et al. Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014;12(2):206\u201313.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"3468_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.thromres.2009.06.035","volume":"124","author":"C Sugita","year":"2009","unstructured":"Sugita C, Yamashita A, Moriguchi-Goto S, Furukoji E, Takahashi M, Harada A, et al. Factor VIII contributes to platelet-fibrin thrombus formation via thrombin generation under low shear conditions. Thromb Res. 2009;124(5):601\u20137.","journal-title":"Thromb Res"},{"key":"3468_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1472-6750-11-114","volume":"11","author":"K Swiech","year":"2011","unstructured":"Swiech K, Kamen A, Ansorge S, Durocher Y, Picanco-Castro V, Russo-Carbolante EM, et al. Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII. BMC Biotechnol. 2011;11:114.","journal-title":"BMC Biotechnol"},{"issue":"3","key":"3468_CR23","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","volume":"117","author":"NJ Ward","year":"2011","unstructured":"Ward NJ, Buckley SM, Waddington SN, Vandendriessche T, Chuah MK, Nathwani AC, et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood. 2011;117(3):798\u2013807.","journal-title":"Blood"},{"issue":"6","key":"3468_CR24","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1128\/JVI.72.6.5085-5092.1998","volume":"72","author":"JE Donello","year":"1998","unstructured":"Donello JE, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol. 1998;72(6):5085\u201392.","journal-title":"J Virol"},{"issue":"4","key":"3468_CR25","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1128\/JVI.73.4.2886-2892.1999","volume":"73","author":"R Zufferey","year":"1999","unstructured":"Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol. 1999;73(4):2886\u201392.","journal-title":"J Virol"},{"issue":"4","key":"3468_CR26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/jth.13632","volume":"15","author":"SA Shestopal","year":"2017","unstructured":"Shestopal SA, Hao JJ, Karnaukhova E, Liang Y, Ovanesov MV, Lin M, et al. Expression and characterization of a codon-optimized blood coagulation factor VIII. J Thromb Haemost. 2017;15(4):709\u201320.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3468_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12896-017-0353-6","volume":"17","author":"NA Orlova","year":"2017","unstructured":"Orlova NA, Kovnir SV, Gabibov AG, Vorobiev II. Stable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based system. BMC Biotechnol. 2017;17(1):33.","journal-title":"BMC Biotechnol"},{"issue":"2","key":"3468_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/mt.2010.239","volume":"19","author":"HT Spencer","year":"2011","unstructured":"Spencer HT, Denning G, Gautney RE, Dropulic B, Roy AJ, Baranyi L, et al. Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII. Mol Ther. 2011;19(2):302\u20139.","journal-title":"Mol Ther"},{"issue":"4","key":"3468_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2516.2010.02454.x","volume":"17","author":"S Grancha","year":"2011","unstructured":"Grancha S, Navajas R, Maranon C, Paradela A, Albar JP, Jorquera JI. Incomplete tyrosine 1680 sulphation in recombinant FVIII concentrates. Haemophilia. 2011;17(4):709\u201310.","journal-title":"Haemophilia"},{"issue":"4","key":"3468_CR30","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/jth.15257","volume":"19","author":"H Chun","year":"2021","unstructured":"Chun H, Pettersson JR, Shestopal SA, Wu WW, Marakasova ES, Olivares P, et al. Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products. J Thromb Haemost. 2021;19(4):954\u201366.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"3468_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3324\/haematol.2016.148502","volume":"102","author":"B Gangadharan","year":"2017","unstructured":"Gangadharan B, Ing M, Delignat S, Peyron I, Teyssandier M, Kaveri SV, et al. The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells. Haematologica. 2017;102(2):271\u201381.","journal-title":"Haematologica"},{"issue":"5","key":"3468_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.blre.2017.07.001","volume":"31","author":"RB Hartholt","year":"2017","unstructured":"Hartholt RB, van Velzen AS, Peyron I, Ten Brinke A, Fijnvandraat K, Voorberg J. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity. Blood Rev. 2017;31(5):339\u201347.","journal-title":"Blood Rev"},{"issue":"11","key":"3468_CR33","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1182\/blood-2018-01-829523","volume":"132","author":"V Muczynski","year":"2018","unstructured":"Muczynski V, Casari C, Moreau F, Ayme G, Kawecki C, Legendre P, et al. A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation. Blood. 2018;132(11):1193\u20137.","journal-title":"Blood"},{"key":"3468_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/1743-422X-9-230","volume":"9","author":"SV Kuchipudi","year":"2012","unstructured":"Kuchipudi SV, Tellabati M, Nelli RK, White GA, Perez BB, Sebastian S, et al. 18S rRNA is a reliable normalisation gene for real time PCR based on influenza virus infected cells. Virol J. 2012;9:230.","journal-title":"Virol J"},{"issue":"10","key":"3468_CR35","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.tips.2013.08.005","volume":"34","author":"C Kimchi-Sarfaty","year":"2013","unstructured":"Kimchi-Sarfaty C, Schiller T, Hamasaki-Katagiri N, Khan MA, Yanover C, Sauna ZE. Building better drugs: developing and regulating engineered therapeutic proteins. Trends Pharmacol Sci. 2013;34(10):534\u201348.","journal-title":"Trends Pharmacol Sci"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03468-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:10:28Z","timestamp":1672841428000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03468-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3468"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03468-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"assertion":[{"value":"6 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TY has received research funding from Bioverativ Inc.\/Sanofi S.A.; KaH, KO, and KyH have no conflict of interest; NS teaches a course endowed by CSL Behring; MS and KN have received research funding from Bioverativ Inc.\/Sanofi S.A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}